We are live on ! Find out more
SCPH

scPharmaceuticals
SCPH

Delisted

SCPH was delisted on the 6th of October, 2025.

Back to rankings

27 hedge funds and large institutions have $62.9M invested in scPharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $44.5M → $62.9M (+$18.4M)

18.92% more ownership

Funds ownership: 40.78% → 59.7% (+19%)

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

4% more funds holding

Funds holding: 26 → 27 (+1)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
5
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
+$637K
2
EP
Eversept Partners
New York
+$409K
3
Squarepoint
Squarepoint
New York
+$280K
4
Renaissance Technologies
Renaissance Technologies
New York
+$264K
5
Deutsche Bank
Deutsche Bank
Germany
+$16.5K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$62K
2
PPA
Parametric Portfolio Associates
Washington
-$60K
3
JP Morgan Chase
JP Morgan Chase
New York
-$44.2K
4
Morgan Stanley
Morgan Stanley
New York
-$25.8K
5
AIM
Alambic Investment Management
California
-$24.5K

SCPH Hedge Fund Activity: Q4 2019 in Review

27 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2019, worth a combined $62.9M — up 41% from $44.5M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new SCPH positions and 9 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Worth Venture Partners, opening a new position worth an estimated $637K. The largest seller was Northern Trust, exiting entirely with an estimated $62K sold.

  • 27 institutional investors held scPharmaceuticals (SCPH) as of Q4 2019, up from 26 in Q3 2019.
  • Funds reported $62.9M of scPharmaceuticals stock for Q4 2019, up 41% quarter-over-quarter.
  • 10 funds opened new scPharmaceuticals positions in Q4 2019 and 9 closed out, a net change of +1 holder.
  • The largest scPharmaceuticals buyer in Q4 2019 was Worth Venture Partners, an estimated $637K added.
  • The largest scPharmaceuticals seller in Q4 2019 was Northern Trust, an estimated $62K sold.

Based on aggregated 13F filings for Q4 2019.